MicroPort Scientific's (HKG:0853) subsidiary Shanghai MicroPort Endovascular MedTech (Group) (SHE:688016) expects to book net profit attributable to equity owners between 492.5 million yuan and 541.0 million yuan for 2024, 0.01% to 9.86% higher than the preceding year, a Monday Hong Kong bourse filing said.
The expected increase was attributed to an increase in overseas revenue and the number of Hospitals entered by Shanghai MicroPort Endovascular MedTech, a continued momentum contributed by its products, and an increase in the number of terminal implants for its new products during the reporting period.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。